Annual Revenue (£)

AstraZeneca revenue was £22.46 b in FY, 2017

FY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017
Revenue£5.36 b£5.19 b£5.51 b£11.35 b£12.10 b£11.43 b£11.14 b£10.53 b£11.47 b£13.95 b£13.53 b£14.83 b£19.83 b£16.91 b£19.63 b£19.14 b£23 b£22.46 b
Growth1.49%(9.4%)(9.82%)
Report incorrect company information

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

AstraZeneca revenue breakdown by business segment: 22.3% from Respiratory, Inflammation and Autoimmunity, 23.8% from Infection, Neuroscience and Gastrointestinal:, 15.9% from Oncology and 38.1% from Cardiovascular and Metabolic Diseases

FY, 2013FY, 2014FY, 2015FY, 2016
Cardiovascular and Metabolic Diseases8.83 b9.80 b9.49 b8.12 b
Oncology3.19 b3.03 b2.83 b3.38 b
Infection, Neuroscience and Gastrointestinal:9.01 b8.20 b6.34 b5.07 b
Respiratory, Inflammation and Autoimmunity4.68 b5.06 b4.99 b4.75 b
Report incorrect company information